Barbara Dalton, PHD is Vice President, WWBD and Senior Managing Partner of Pfizer Ventures. Barbara has been a member of Pfizer’s Worldwide Business Development Leadership Team for the past 15 years where she is responsible for leading Pfizer Ventures, managing the corporation’s private equity portfolio, as well as overseeing equity-based transactions that support business development. In addition to leading the venture team, she currently has responsibility for Pfizer’s investments in AMRA Medical, Artios Pharma, IMARA,Ixchelsis, Levicept, National RSILIENCE, Prescriber Point, Priovant, Saama Technologies, Second Genome, Simcha Therapeutics and many fund investments. Prior Pfizer Ventures investment responsibilities include 4DMolecular Therapeutics, Ablexis, Accelerator, BioNTech, Cydan, Complexa, Lodo, Morphic Therapeutic, NexImmune, Petra Pharma, Rhythm Pharmaceuticals, SpringWorks Therappeutics, System1, Vtesse. and Yumanity

Barbara has spent over 30 years in the pharmaceutical industry, most of that time as a corporate venture capitalist. She joined SmithKline’s venture capital group, S.R. One, Limited in the early 1990s and was a founding member of EuclidSR Partners, a related private New York based venture capital firm, in 2000. Barbara began her career as a research scientist, pursuing anti-inflammatory drug discovery research at SmithKline and French Research Laboratories. Barbara has been a leader in the corporate venture capital world, establishing the Corporate Venture Capital Group within the National Venture Capital Association (NVCA). She has been on the board of the NVCA< Alzheimer’s Disease Research Foundation, the NYBio organization and currently Chairs the Healthcare group of the Partnership Fund for New York City.

Barbara received a BS in General Science from Penn State and a PhD in Microbiology and Immunology from the Medical College of Pennsylvania, now the Drexel University College of Medicine.